Eric Huang1,2, Malgorzata Maciukiewicz2, Clement C Zai2, Arun K Tiwari2, Jiang Li3, Steven G Potkin4, Jeffrey A Lieberman5, Herbert Y Meltzer3, Daniel J Müller2,6, James L Kennedy2,6. 1. 1 King's College Circle, Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada. 2. 250 College Street, Pharmacogenetic Research Clinic, Centre for Addiction & Mental Health, Toronto, ON, M5T 1R8, Canada. 3. 303 East Chicago Avenue, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. 4. 5251 California Avenue, Department of Psychiatry & Human Behavior, University of California, Irvine, CA 92617, USA. 5. 1051 Riverside Drive, Department of Psychiatry, Columbia University Medical Center, New York, NY 10032, USA. 6. 250 College Street, Department of Psychiatry, University of Toronto, Toronto, ON, M5T 1R8, Canada.
Abstract
AIM: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. PATIENTS & METHODS: We investigated the SNP in relation to treatment response in a prospective study consisting of 208 patients (151 Caucasians, 42 African-Americans and 15 others) treated with clozapine for 6 months. RESULTS: rs2514218 was associated with total score change in the brief psychiatric rating scale under an additive model (pcorr= 0.033). CONCLUSION: Our finding provides evidence for rs2514218 association with antipsychotic response, but further replication is required before firm conclusions can be drawn.
AIM: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. PATIENTS & METHODS: We investigated the SNP in relation to treatment response in a prospective study consisting of 208 patients (151 Caucasians, 42 African-Americans and 15 others) treated with clozapine for 6 months. RESULTS: rs2514218 was associated with total score change in the brief psychiatric rating scale under an additive model (pcorr= 0.033). CONCLUSION: Our finding provides evidence for rs2514218 association with antipsychotic response, but further replication is required before firm conclusions can be drawn.
Authors: Carolina C Toste; Rodrigo R R Duarte; Aaron R Jeffries; Sashika Selvackadunco; Claire Troakes; Michael C O'Donovan; Matthew J Hill; Nicholas J Bray Journal: Mol Neuropsychiatry Date: 2019-07-15
Authors: Margarita V Alfimova; Nikolay V Kondratyev; Alexander S Tomyshev; Irina S Lebedeva; Tatyana V Lezheiko; Vasiliy G Kaleda; Lilia I Abramova; Vera E Golimbet Journal: J Mol Neurosci Date: 2019-05-03 Impact factor: 3.444
Authors: Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn Journal: Front Neurosci Date: 2018-01-22 Impact factor: 4.677
Authors: Ruta Samanaite; Amy Gillespie; Kyra-Verena Sendt; Grant McQueen; James H MacCabe; Alice Egerton Journal: Front Psychiatry Date: 2018-07-26 Impact factor: 4.157